Company Profile
Medicalsystem Biotechnology Co., Ltd. is a China-based manufacturer of in vitro diagnostic (IVD) reagents and instruments, headquartered in Ningbo, Zhejiang, China. Founded on July 22, 2003 by Zou Bingde, the company operates as a publicly listed entity on the Shenzhen Stock Exchange ChiNext Board (300439), serving global clinical diagnostics markets through an integrated business model spanning self-produced IVD products, agency distribution, and third-party medical diagnostic services.
Core Products ＆ Technologies
IVD Reagents
• Clinical Chemistry Reagents: Biochemistry diagnostic kits for liver function, renal function, lipids, glucose, and cardiac markers
• Immunoassay Reagents: Chemiluminescence and ELISA-based kits for tumor markers, thyroid function, fertility hormones, and infectious disease serology
• Molecular Diagnostic Reagents: Nucleic acid amplification kits for pathogen detection and genetic testing
• POCT Reagents: Rapid test strips and cartridges for point-of-care emergency and primary care screening
IVD Instruments
• Automatic Biochemistry Analysers: High-throughput clinical chemistry systems for core laboratory workflow automation
• Automatic Immunoassay Analysers: Chemiluminescence immunoassay platforms for quantitative biomarker detection
• POCT Analysers: Compact, rapid-response devices for bedside and outpatient diagnostic testing
Third-Party Medical Diagnostics
• Medical Diagnostic Services: Independent clinical laboratory offering pathology, biochemistry, immunology, microbiology, and molecular testing for hospitals and clinics
• Health Screening Services: Preventive health check-up and wellness screening programs
Market Position ＆ Certifications
Medicalsystem Biotechnology holds a leading domestic position in China's IVD reagent and instrument market, competing with Roche Diagnostics, Abbott Laboratories, and Siemens Healthineers in the clinical diagnostics segment. Key strengths include:
• 23 years of Chinese IVD industry heritage since founding
• Integrated vertical model: Self-developed reagents paired with proprietary instruments and third-party lab services
• Regulatory compliance: NMPA Class II and Class III registrations for reagents and analysers; ISO 13485 quality management certification
• Hospital network: Products and services deployed across thousands of medical institutions in China
• Global footprint: Overseas operations through subsidiaries in the United States (San Diego), Hong Kong, and Japan
Corporate Timeline
2003 — Founded in Ningbo, Zhejiang, China, as Ningbo Medicalsystem Biotechnology Co., Ltd.
2011 — Reorganized into a joint-stock company
2015 — Completed IPO on the Shenzhen Stock Exchange ChiNext Board (300439)
2017 — Company name changed to Medicalsystem Biotechnology Co., Ltd.; expanded national distribution network
2024 — Life Health Industrial Park project completed and transferred to fixed assets
2025 — Full-year revenue reached RMB 1.54 billion (-11.67% YoY); net profit RMB 63.2 million (-75.50% YoY); R＆D investment RMB 127.2 million (-13.16% YoY); maintained distribution network of 1,800+ dealers
Target Markets ＆ Applications
• Core Laboratory Diagnostics: High-volume biochemistry and immunoassay testing in hospital central labs and independent clinical laboratories
• Point-of-Care Testing: Rapid cardiac, infectious disease, and metabolic screening in emergency departments and primary care clinics
• Third-Party Lab Services: Outsourced pathology and specialty testing for regional hospitals and health screening centers
• Reproductive ＆ Thyroid Health: Hormone panels and tumor marker assays for endocrinology and obstetrics/gynecology departments
Contact Information
Global Headquarters
Address: No. 299 Qiming South Road, Yinzhou District, Ningbo, Zhejiang 315104, China
Office Address: No. 1228 Jinda South Road, Yinzhou District, Ningbo, Zhejiang 315104, China
Telephone: +86 574 8817 8818
Fax: +86 574 8817 8518
Email: mksw@nbmksw.com
Corporate Status
Entity Type: Publicly Listed Company (No Parent Company)
Stock: Shenzhen Stock Exchange ChiNext: 300439
Website: nbmedicalsystem.com
Investor Relations: mksw@nbmksw.com
